Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

Similar articles for PubMed (Select 21492993)

1.

Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.

Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert C, Treluyer JM, Herinomenzanahary E, Ferreira C, Peytavin G.

Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):18-21. doi: 10.1016/j.ejogrb.2011.02.005. Epub 2011 Apr 13.

PMID:
21492993
2.

Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.

Eley T, Huang SP, Conradie F, Zorrilla CD, Josipovic D, Botes M, Osiyemi O, Hardy H, Bertz R, McGrath D.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1287-92. doi: 10.1089/AID.2013.0002. Epub 2013 Jul 19.

3.

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.

AIDS. 2007 Nov 30;21(18):2409-15.

PMID:
18025877
4.

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

Ther Drug Monit. 2007 Oct;29(5):648-51.

PMID:
17898658
5.

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.

AIDS. 2006 May 12;20(8):1131-9.

PMID:
16691064
6.

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.

Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, Soriano V.

AIDS. 2007 Jan 2;21(1):41-6.

PMID:
17148966
7.

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.

Di Biagio A, Rosso R, Loregian A, Pagni S, Sormani MP, Cenderello G, Palù G, Viscoli C.

J Infect Chemother. 2012 Aug;18(4):587-90. doi: 10.1007/s10156-012-0402-y. Epub 2012 Mar 16.

PMID:
22422300
8.

Atazanavir/ritonavir: a review of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. Review.

PMID:
18389089
9.

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

Rodríguez-Nóvoa S, Morello J, Barreiro P, Maida I, García-Gascó P, Vispo E, González-Pardo G, Parra A, Jiménez-Nácher I, Soriano V.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):821-5. doi: 10.1089/aid.2007.0276.

PMID:
18507524
10.

[Pharmacology, pharmacokinetic features and interactions of atazanavir].

López-Cortés LF.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:2-8. doi: 10.1016/S0213-005X(08)76613-8. Review. Spanish.

PMID:
20116610
11.

Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.

HIV Med. 2010 May;11(5):326-33. doi: 10.1111/j.1468-1293.2009.00785.x. Epub 2010 Dec 9.

PMID:
20070407
12.
13.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

PMID:
18294112
14.

High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.

Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

Clin Infect Dis. 2012 Nov;55(9):1262-9. doi: 10.1093/cid/cis621. Epub 2012 Jul 19.

15.

[Utility of atazanavir in special populations].

Antela López A.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:49-54. doi: 10.1016/S0213-005X(08)76621-7. Review. Spanish.

PMID:
20116618
16.

Predictors of virological response to atazanavir in protease inhibitor-experienced patients.

Barrios A, Rendón AL, Gallego O, Martín-Carbonero L, Valer L, Ríos P, Maida I, García-Benayas T, Jiménez-Nácher I, González-Lahoz J, Soriano V.

HIV Clin Trials. 2004 Jul-Aug;5(4):201-5.

PMID:
15472794
17.

Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnuovo F, Maggiolo F, De Luca A, Paraninfo G, Antonucci F, Migliorino G, Lazzarin A, Di Perri G, Rizzardini G, Esposito R, Carosi G.

Infection. 2009 Jun;37(3):244-9. doi: 10.1007/s15010-008-8010-6. Epub 2009 May 26.

PMID:
19471856
18.

[Clinical utility of atazanavir].

Ribera Pascuet E, Curran A.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:55-67. doi: 10.1016/S0213-005X(08)76622-9. Review. Spanish.

PMID:
20116619
19.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team.

Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

PMID:
18722869
20.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group.

J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk